SNG001

This page shows the latest SNG001 news and features for those working in and with pharma, biotech and healthcare.

Positive COPD data for Synairgen's SNG001 supports COVID-19 programme

Interim analysis from the phase 2 trial in COPD patients with confirmed respiratory viral infection found that treatment with SNG001 improved lung antiviral responses compared to placebo. ... In exacerbating patients who already required treatment with

Latest news

UK biotech Synairgen reveals promising early results for COVID-19 drug

The double-blind, placebo-controlled phase 1 trial of SNG001 recruited 101 hospitalised COVID-19 patients from nine hospital sites across the UK. ... While three patients died after being randomised to receive the placebo, no deaths were observed among
UK biotech Synairgen to begin COVID-19 trial of lead candidate

SNG001 (inhaled formulation of interferon-beta-1a), as concerns grow in the UK that COVID-19 cases could soar in the comings weeks. ... SNG001 delivers a formulation of INF-beta-1a to the lungs directly via nebulisation, and is suitable for inhaled
AZ licenses asthma infection drug from Synairgen

The novel formulation - called SNG001 - is designed to prevent the sometimes severe exacerbations suffered by asthma patients when they develop respiratory viral infections such as colds. ... The big pharma company will also meet all future development

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Pharma deals during June 2014

Clearly not deterred by this, AZ has moved on to build on its respiratory franchise by in-licensing Synairgen's inhaled beta interferon SNG001.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
How COVID-19 is accelerating the threat of antimicrobial resistance: Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...